A Phase 3 interventional study of Aspirin (Acetylsalicylic acid, BAYE4465) and Placebo in Moderate Risk of CVD, sponsored by Bayer. Completed at 466 sites in 8 countries. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2018-10-26.
Sponsored by Bayer · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies testing aspirin in Stroke — 8 open to participants now, 10 under way, 3 of them phase 3. Aspirin · Stroke.
Among the 42 studies testing aspirin in Stroke, this one is the 3rd largest by enrollment of the 41 interventional ones that give a count, is one of 4 that started in 2007, is one of 11 in phase 3, and was the 7th registered.
8,269 studies on the registry are indexed under Stroke; 2,067 are open to participants now.
Browse Stroke studies →8 of the 42 studies testing aspirin in Stroke are open now, in 5 countries. Recruiting first, the newest first:
Christian Medical College and Hospital, Ludhiana, India · Sites in India
Ages 18–99
Chinese Academy of Medical Sciences, Fuwai Hospital · Sites in China
Xueli Cai · Sites in China
Ages 18–85
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
University Hospital, Bordeaux · Sites in France
Ages 18+
By country, each count listing its studies:
Aspirin: first FDA approval 1950 (PERCODAN), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 1,421 Stroke studies recruiting now, 696 (49%) set no upper age limit and 284 (20%) stop at 75 or younger; 77 take children under 18; 198 take healthy volunteers.
This study: 55 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 13 · Phase 4 17
First in 2002; this study’s year is marked. 4 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 12,546 is above the median of 49 across 6,043 interventional studies indexed under Stroke.
Median enrollment 675 across the 41 interventional studies. Of the 24 that completed or were terminated, 6 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 42 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
29 studies in Stroke by Bayer: none open now, none under way, none of them phase 3. Of 29 finished, 5 (17%) have results posted.
Among the 29 studies in Stroke by Bayer, this one is the only one that started in 2007, is one of 6 in phase 3, and was the 2nd registered.
Bayer’s Stroke studies by the year they started, since 2000.
3 of the studies testing aspirin in Stroke that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05047172Phase 3University of FloridaComparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis | 2027-01-31 |
| NCT05476991Phase 3Assistance Publique - Hôpitaux de ParisEvaluation of Low Dose Colchicine and Ticagrelor in Prevention of Ischemic Stroke in Patients With Stroke Due to Atherosclerosis | 2027-09-01 |
| NCT04796714University Hospital, BordeauxAntiPlatelet theraPy stratEgy followiNg Left Atrial appenDAGe closurE | 2027-05-03 |
Add all 3 to your calendar (.ics) → With an account.
Among the 42 studies testing aspirin in Stroke, from their registry updates:
Among Bayer’s 29 in Stroke:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The use of acetylsalicylic acid in the primary prevention of cardiovascular events has been extensively studied but to a lesser extent in patients with moderate levels of cardiovascular risk. The current study is designed to prove the efficacy and tolerability of 100 mg enteric-coated Aspirin versus placebo in the prevention of cardiovascular disease (CVD) events, which include fatal and nonfatal myocardial infarction, fatal and nonfatal stroke and CV death, in a population with no history of known CVD who are at moderate risk of major CHD events (approximately 10-20% 10 year CHD risk). This corresponds to a patient population mean 10-year CVD risk of approximately 30%. Subjects are treated in a standard care setting and may receive treatment for the underlying risk factors as defined by the treating physician. Outcome events will be adjudicated by an Endpoint Adjudication Committee and the study will be monitored by an independent Data Safety Monitoring Board.
Summary of substantial Protocol amendments
Amendment #2 from 09-APR-2008:
Amendment #3 from 02-JAN-2009
Amendment #4 from 02-OCT-2013
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Males aged 55 years and above with 2 to 4 risk factors. Male Risk Factors:
Females aged 60 and above with 3 or more risk factors. Female Risk Factors:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 1 tablet of enteric-coated acetylsalicylic acid \[100 milligram (mg)\] orally once daily.
Drug: Aspirin (Acetylsalicylic acid, BAYE4465)
Participants received 1 tablets of matching placebo orally once daily.
Drug: Placebo
100mg enteric coated Aspirin, taken daily
Placebo, taken daily
Time to the First Occurrence of the Composite Outcome of MI (Myocardial Infarction), Stroke, Cardiovascular Death, UA (Unstable Angina) or TIA (Transient Ischemic Attack)
The primary efficacy endpoint was a composite outcome consisting of the first occurrence of confirmed MI, stroke, cardiovascular death, UA, TIA. The time to event was defined as the number of days from the date of randomization to the date of the event confirmed by adjudication. The numbers of days for milestones when 1%, 2%, 3% and 4% of the subjects have reached endpoint events were estimated from Kaplan-Meier-Analyses.
Time frame: Until follow-up (approximate 6 years)
Time to the First Occurrence of the Composite Outcome of Cardiovascular Death, MI, or Stroke (Ischemic, Hemorrhagic, or Unknown)
The time to Composite outcome consisting of the first occurrence of cardiovascular death, MI, or stroke (ischemic, hemorrhagic, or unknown) was defined as the number of days from the date of randomization to the date of the event confirmed by adjudication. The numbers of days for milestones when 1%, 2%, 3% and 4% of the subjects have reached endpoint events were estimated from Kaplan-Meier-Analyses.
Time frame: Until follow-up (approximate 6 years)
Time to the First Occurrence of the Individual Components of the Primary: Non-fatal MI, Total MI, Non-fatal Stroke, Total Stroke, Cardiovascular Death, UA and TIA
The time to event was defined as the number of days from the date of randomization to the date of the event confirmed by adjudication. The numbers of days for milestones when 1%, 2%, 3% and 4% of the subjects have reached endpoint events were estimated from Kaplan-Meier-Analyses.
Time frame: Until follow-up (approximately 6 years)
Time to All-cause Mortality, the First Occurrence of All Cancers Excluding Non-melanoma Skin Cancer (NMSC) and the First Occurrence of Colon Cancer
The time to event was defined as the number of days from the date of randomization to the date of the event confirmed by adjudication. The numbers of days for milestones when 1%, 2%, 3% and 4% of the subjects have reached endpoint events were estimated from Kaplan-Meier-Analyses.
Time frame: Until follow-up (approximately 6 years)
Incidence of All-cause Mortality, All Cancers Excluding Non-melanoma Skin Cancer and Colon Cancer
Time frame: Until follow-up (approximately 6 years)
Incidence of Confirmed MI, Stroke, Cardiovascular Death, UA, and TIA Separately
The percentages of subjects with the efficacy endpoints of confirmed MI, stroke, cardiovascular death, UA and TIA are reported separately. \*all other CV death without fatal MI and fatal stroke
Time frame: Until follow-up (approximately 6 years)
Number of Subjects With Adjudicated GI Bleeding by Severity
Time frame: Until follow-up (approximate 6 years)
Incidence of Composite Outcomes and Non-fatal MI
Time frame: Until follow-up (approximate 6 years)
Incidence of Composite Outcomes and Individual Outcomes in Per-protocol Population
\*all other CV death without fatal MI and fatal stroke.
Time frame: Until follow-up (approximate 6 years)
Overall, 15823 subjects were screened. Of these, 3277 subjects were screening failures. The remaining 12546 subjects were randomized to treatment.
| Milestone | Acetylsalicylic Acid (Aspirin, BAYE4465) | Placebo |
|---|---|---|
| Started | 6270 | 6276 |
| Completed | 4402 | 4384 |
| Not completed | 1868 | 1892 |
| Withdrew: Protocol violation | 80 | 69 |
| Withdrew: Death | 140 | 137 |
| Withdrew: Other | 236 | 239 |
| Withdrew: Missing end-of-study page | 91 | 92 |
| Withdrew: Clinical endpoint reached | 110 | 123 |
| Withdrew: Insufficient therapeutic effect | 4 | 5 |
| Withdrew: Consent withdrawn by subject | 817 | 873 |
| Withdrew: Non-compliant with study treatment | 23 | 16 |
| Withdrew: Reason not given | 3 | 1 |
| Withdrew: Adverse event | 129 | 122 |
| Withdrew: Lost to follow-up | 210 | 198 |
| Withdrew: Not treated | 25 | 17 |
The primary efficacy endpoint was a composite outcome consisting of the first occurrence of confirmed MI, stroke, cardiovascular death, UA, TIA. The time to event was defined as the number of days from the date of randomization to the date of the event confirmed by adjudication. The numbers of days for milestones when 1%, 2%, 3% and 4% of the subjects have reached endpoint events were estimated from Kaplan-Meier-Analyses.
| Days | Acetylsalicylic Acid (Aspirin, BAYE4465) | Placebo |
|---|---|---|
| Days until 1% subjects had an efficacy event | 528 | 381 |
| Days until 2% subjects had an efficacy event | 889 | 796 |
| Days until 3% subjects had an efficacy event | 1225 | 1134 |
| Days until 4% subjects had an efficacy event | 1630 | 1582 |
The time to Composite outcome consisting of the first occurrence of cardiovascular death, MI, or stroke (ischemic, hemorrhagic, or unknown) was defined as the number of days from the date of randomization to the date of the event confirmed by adjudication. The numbers of days for milestones when 1%, 2%, 3% and 4% of the subjects have reached endpoint events were estimated from Kaplan-Meier-Analyses.
| Days | Acetylsalicylic Acid (Aspirin, BAYE4465) | Placebo |
|---|---|---|
| Days until 1% subjects had an efficacy event | 678 | 522 |
| Days until 2% subjects had an efficacy event | 1167 | 1053 |
| Days until 3% subjects had an efficacy event | 1599 | 1501 |
| Days until 4% subjects had an efficacy event | 1949 | 1930 |
The time to event was defined as the number of days from the date of randomization to the date of the event confirmed by adjudication. The numbers of days for milestones when 1%, 2%, 3% and 4% of the subjects have reached endpoint events were estimated from Kaplan-Meier-Analyses.
| Days | Acetylsalicylic Acid (Aspirin, BAYE4465) | Placebo |
|---|---|---|
| Days until 1% subjects had non-fatal MI | 1309 | 1085 |
| Days until 2% subjects had non-fatal MI | NA | 2121 |
| Days until 1% subjects had total MI | 1216 | 1014 |
| Days until 2% subjects had total MI | 2128 | 1906 |
| Days until 1% subjects had non-fatal stroke | 1576 | 1650 |
| Days until 2% subjects had non-fatal stroke | NA | NA |
| Days until 1% subjects had total stroke | 1543 | 1627 |
| Days until 2% subjects had total stroke | NA | NA |
| Days until 1% subjects had cardiovascular death | NA | NA |
| Days until 2% subjects had cardiovascular death | NA | NA |
| Days until 1% subjects had UA | NA | NA |
| Days until 2% subjects had UA | NA | NA |
| Days until 1% subjects had TIA | NA | NA |
| Days until 2% subjects had TIA | NA | NA |
The time to event was defined as the number of days from the date of randomization to the date of the event confirmed by adjudication. The numbers of days for milestones when 1%, 2%, 3% and 4% of the subjects have reached endpoint events were estimated from Kaplan-Meier-Analyses.
| Days | Acetylsalicylic Acid (Aspirin, BAYE4465) | Placebo |
|---|---|---|
| Days until 1% subjects had all-cause mortality | 838 | 938 |
| Days until 2% subjects had all-cause mortality | 1493 | 1460 |
| Days until 3% subjects had all-cause mortality | 1970 | 1963 |
| Days until 4% subjects had all-cause mortality | NA | NA |
| Days until 1% subjects had all cancer excl. NMSC | 374 | 420 |
| Days until 2% subjects had all cancer excl. NMSC | 849 | 805 |
| Days until 3% subjects had all cancer excl. NMSC | 1164 | 1276 |
| Days until 4% subjects had all cancer excl. NMSC | 1542 | 1751 |
| Days until 1% subjects had colon cancer | NA | NA |
| Days until 2% subjects had colon cancer | NA | NA |
| Days until 3% subjects had colon cancer | NA | NA |
| Days until 4% subjects had colon cancer | NA | NA |
| Percentage of participants | Acetylsalicylic Acid (Aspirin, BAYE4465) | Placebo |
|---|---|---|
| all-cause mortality | 2.55 | 2.57 |
| all cancers excluding non-melanoma skin cancer | 4.02 | 3.76 |
| colon cancer | 0.48 | 0.41 |
The percentages of subjects with the efficacy endpoints of confirmed MI, stroke, cardiovascular death, UA and TIA are reported separately. \*all other CV death without fatal MI and fatal stroke
| Percentage of participants | Acetylsalicylic Acid (Aspirin, BAYE4465) | Placebo |
|---|---|---|
| MI | 1.52 | 1.78 |
| stroke | 1.20 | 1.07 |
| CV death* | 0.61 | 0.62 |
| UA | 0.32 | 0.32 |
| TIA | 0.67 | 0.72 |
| Participants | Acetylsalicylic Acid (Aspirin, BAYE4465) | Placebo |
|---|---|---|
| Total | 61 | 29 |
| Mild | 42 | 22 |
| Moderate | 15 | 5 |
| Severe | 4 | 2 |
| Percentage of participants | Acetylsalicylic Acid (Aspirin, BAYE4465) | Placebo |
|---|---|---|
| MI, stroke, CV death, UA or TIA | 4.29 | 4.48 |
| MI, stroke or CV death | 3.32 | 3.47 |
| non-fatal MI | 1.40 | 1.56 |
\*all other CV death without fatal MI and fatal stroke.
| Percentage of participants | Acetylsalicylic Acid (Aspirin, BAYE4465) Per-protocol | Placebo Per-protocol |
|---|---|---|
| MI, stroke, CV death, UA or TIA | 3.40 | 4.19 |
| MI, stroke or CV death | 2.72 | 3.45 |
| MI | 0.98 | 1.84 |
| Non-fatal MI | 0.84 | 1.53 |
| Stroke | 1.06 | 0.95 |
| CV death* | 0.69 | 0.66 |
| UA | 0.21 | 0.28 |
| TIA | 0.50 | 0.49 |
| All-cause mortality | 2.85 | 2.58 |
Collected over Until follow-up (approximately 6 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 1,311/6,276 (20.9%) | 5,053/6,276 (80.5%) |
| Acetylsalicylic Acid | — | 1,266/6,270 (20.2%) | 5,059/6,270 (80.7%) |
| Event | Placebo | Acetylsalicylic Acid |
|---|---|---|
| OsteoarthritisMusculoskeletal and connective tissue disorders | 103/6276 | 104/6270 |
| Coronary artery diseaseCardiac disorders | 61/6276 | 46/6270 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 44/6276 | 59/6270 |
| Acute myocardial infarctionCardiac disorders | 58/6276 | 43/6270 |
| Atrial fibrillationCardiac disorders | 40/6276 | 37/6270 |
| Myocardial infarctionCardiac disorders | 38/6276 | 29/6270 |
| Inguinal herniaGastrointestinal disorders | 31/6276 | 35/6270 |
| Transient ischaemic attackNervous system disorders | 30/6276 | 26/6270 |
| PneumoniaInfections and infestations | 19/6276 | 26/6270 |
| CholelithiasisHepatobiliary disorders | 17/6276 | 24/6270 |
| Event | Placebo | Acetylsalicylic Acid |
|---|---|---|
| Back painMusculoskeletal and connective tissue disorders | 688/6276 | 695/6270 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 653/6276 | 636/6270 |
| BronchitisInfections and infestations | 482/6276 | 514/6270 |
| HypertensionVascular disorders | 514/6276 | 478/6270 |
| CoughRespiratory, thoracic and mediastinal disorders | 497/6276 | 442/6270 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 423/6276 | 468/6270 |
| NasopharyngitisInfections and infestations | 407/6276 | 421/6270 |
| Lower respiratory tract infectionInfections and infestations | 420/6276 | 377/6270 |
| DyspepsiaGastrointestinal disorders | 362/6276 | 374/6270 |
| Upper respiratory tract infectionInfections and infestations | 371/6276 | 348/6270 |
| Age, Continuous(Years) | Acetylsalicylic Acid (Aspirin, BAYE4465) | Placebo | Total |
|---|---|---|---|
| Mean | 63.9 ± 7.10 | 63.9 ± 7.05 | 63.9 ± 7.08 |
| Sex: Female, Male(Participants) | Acetylsalicylic Acid (Aspirin, BAYE4465) | Placebo | Total |
|---|---|---|---|
| Female | 1851 | 1857 | 3708 |
| Male | 4419 | 4419 | 8838 |
Showing the first 100 of 466 sites across 8 countries. Choose a country and city above to see the rest.
Ran from Jul 2007 to primary completion in Nov 2016, 112 months.
Results were first posted in Jan 2018, 1 year 1 month after primary completion. A results delay was requested in Sep 2017.
Of 37 industry-sponsored phase 3 interventional studies under Stroke, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 58. This study's 112 months is above that.
Counting every sponsor, half of 129 studies reached it within 44 months; a quarter within 27 and three quarters within 68.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aspirin